Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-AIO in Relapsed/Refractory B-cell Lymphoma
NCT05318963Phase 1Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2022
- Primary completion
- Jan 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-AIO in B cell lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Treatment-emergent Adverse Events at 2 years, Pharmacokinetics in peripheral blood at 2 years and 2 more. Started Mar 2022; status: terminated.
02
Drugs
LCAR-AIO
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT05318963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318963.